Sarepta Therapeutics (SRPT) Receivables - Net (2010 - 2026)

Sarepta Therapeutics' Receivables - Net history runs 17 years deep, the most recent figure standing at $394.8 million for Q1 2026.

• In Q1 2026, Receivables - Net fell 40.12% year-over-year to $394.8 million; the TTM figure through Mar 2026 stood at $394.8 million (down 40.12% YoY), while the FY2025 annual figure was $398.2 million, down 33.85% from the prior year.
• Receivables - Net was $394.8 million for Q1 2026 at Sarepta Therapeutics, down from $398.2 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $659.4 million in Q1 2025 to a low of $178.2 million in Q1 2022.
• Historically, Receivables - Net has averaged $360.5 million across 5 years, with a median of $378.8 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Receivables - Net soared 86.55% in 2023, then sank 40.12% in 2026.
• A 5-year view of Receivables - Net shows it stood at $214.6 million in 2022, then jumped by 86.55% to $400.3 million in 2023, then jumped by 50.37% to $602.0 million in 2024, then plunged by 33.85% to $398.2 million in 2025, then slipped by 0.86% to $394.8 million in 2026.
• The last three Receivables - Net figures came in at $394.8 million (Q1 2026), $398.2 million (Q4 2025), and $395.7 million (Q3 2025), per Business Quant data.